Ml Delaney

Ml Delaney

Auto-generated profile, based on publicly available information

Ml Delaney

Massachusetts Host-Microbiome Center, Dept. Pathology, Brigham & Women’s Hospital, Harvard Medical School. Boston, MA 02115

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
BYBinglan Yu
Binglan Yu
BFBijan Safaee Fakhr
Bijan Safaee Fakhr
LBLynn Bry
Lynn Bry
ASAngela Shih
Angela Shih
HWHatus V. Wanderley
Hatus V. Wanderley
LBLorenzo Berra
Lorenzo Berra
Antibiotic resistance in respiratory infections is an escalating global concern that requires innovative antimicrobial approaches. Pseudomonas aeruginosa is a common multidrug-resistant pathogen and a major cause of hospital-acquired pneumonia. Accumulating evidence suggests that, at high doses, inhaled nitric oxide (iNO) acts as a potent antimicrobial agent. This study evaluated the efficacy and safety of iNO at 300 parts per million (iNO 300 ) as a treatment for P. aeruginosa infection. In vitro, P. aeruginosa exhibited a dose-dependent reduction when exposed to an NO donor. In a mechanically ventilated swine model of P. aeruginosa pneumonia, intermittent iNO 300 therapy resulted in a two-log reduction in bacterial burden, improved oxygenation and lung compliance, and reduced histopathological lung injury. A phase 1 clinical trial in 10 healthy individuals confirmed the safety of intermittent iNO 300 therapy with no adverse events. In two critically ill patients with multidrug-resistant bacteria, who were in the intensive care unit, iNO 300 was well tolerated, demonstrating clinical feasibility. Long-term follow-up of patients exposed to high-dose iNO for more than 6 years revealed no adverse outcomes. Our findings establish iNO 300 as a promising antimicrobial agent against P. aeruginosa pneumonia, warranting further clinical evaluation.

3 March 2022 in STAR Protocols
Verified
Journal Article
Open access
APAidan Pavao
Aidan Pavao
MGMadeline Graham
Madeline Graham
OTOlivia Trofimuk
Olivia Trofimuk
MDMary L. Delaney
Mary L. Delaney
VYVladimir Yeliseyev
Vladimir Yeliseyev
LBLynn Bry
Lynn Bry
Here, we present a protocol for the use of negative pressure isolator systems to maintain defined association and contain BSL-2 pathogens in germ-free and gnotobiotic mouse studies. We describe setup and operation of negative pressure isolators with integrated microbiologic procedures, using the BSL-2 pathogen Clostridioides difficile as a working example. This approach supports experimental systems with defined-association mice and enables high-resolution mechanistic studies of pathogen-commensal interactions and their impacts on host phenotypes.

12 June 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
MGM Graham
M Graham
NDN DiBenedetto
N DiBenedetto
MDMl Delaney
Ml Delaney
RLR Lavin
R Lavin
APA Pavao
A Pavao
LBL Bry
L Bry
The commensal Clostridium scindens has been regarded as a promising bacteriotherapeutic against Clostridioides difficile infection due to its ability to consume host factors that can promote C. difficile growth, and its production of the antimicrobial compound 1-acetyl-β-carboline. We investigated C. scindens’ protective effects against C. difficile using defined colonization studies in gnotobiotic mice. Mice infected with C. difficile develop lethal infection within 48 hours. In contrast, 88% of mice pre-colonized with C. scindens survived acute infection with delayed C. difficile colonization, lower biomass, and toxin B levels at 24 hours after infection. However, two weeks post-challenge, surviving mice showed comparable levels of cecal C. difficile vegetative and spore biomass and toxin B, as seen during acute infection. After two weeks, co-colonized mice exhibited mucosal colonic hyperplasia with focal pseudomembranes, modeling a chronic and recurrent infection state. Our findings illustrate how the commensal microbiota can modulate host and pathogen interactions leading to chonic C. difficile carriage and infection.

24 October 2023 in medRxiv
Verified
Preprint
Open access
PDF file
JWJay Noboru Worley
Jay Noboru Worley
NBNicholas D. Benedetto
Nicholas D. Benedetto
MDMary Delaney
Mary Delaney
APAna Oliveira Paiva
Ana Oliveira Paiva
MCMarie-Pierre Chapot-Chartier
Marie-Pierre Chapot-Chartier
LBLynn Bry
Lynn Bry
Cephalosporins are the most common triggers of healthcare-associated Clostridioides difficile infections (CDI). Here, we confirm gene-level drivers of cephalosporin resistance and their roles in promoting disease. Genomic-epidemiologic analyses of 306 C. difficile isolates from a hospital surveillance program monitoring asymptomatic carriers and CDI patients identified prevalent third-generation cephalosporin resistance to ceftriaxone at >256 ug/mL in 26% of isolates. Resistance was associated with patient cephalosporin exposures 8-10 days before C. difficile detection. Genomic analyses identified variants in the mreE penicillin binding protein 2 (PBP2) associated with resistance to multiple beta-lactam classes. Transfer of variants into susceptible strain CD630 elevated resistance to first and third-generation cephalosporins. Transfer into the mouse-infective strain ATCC 43255 enabled disease when mice were exposed to 500ug/mL cefoperazone, a dose that inhibited the isogenic susceptible strain. Our findings establish roles of cephalosporins and mreE -cephalosporin-resistant variants in CDI and provide testable genetic loci for detecting resistance in patient strains.

23 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
LCLaura Marie Cersosimo
Laura Marie Cersosimo
NCN Correa
N Correa
MDMl Delaney
Ml Delaney
LDL DelloStritto
L DelloStritto
MMM Misialek
M Misialek
LBL Bry
L Bry
Clostridioides difficile is the leading cause of healthcare acquired infections (HAIs). Healthcare systems lack scalable strategies to identify patients colonized with toxigenic strains to inform prevention programs. We developed a scalable program using rectal swabs, collected for vancomycin resistance Enterococci surveillance, with ex vivo amplification of C. difficile in Cdiff Banana Broth (BB). Optimized confirmatory testing of BB-positive tubes used the rapid C. difficile QuickCheck assay with Cepheid’s Xpert® C. difficile/Epi (Xpert) to confirm toxin gene carriage for QuickCheck results of C. difficile glutamate dehydrogenase-positive (GDH) and antigenic toxin-negative. BB with confirmation demonstrated 92% specificity and 100% sensitivity, to a limit of <5 colony forming units (CFU)/swab, versus published values of 100/swab by ChromID® C. difficile agar and 460/swab by direct Xpert swab testing. The two-step confirmation detected toxigenic C. difficile in cases missed by other methods. Prospective testing of 797 VRE swabs from 538 ICU and inpatient oncology patients seen at an academic medical center and two community hospitals demonstrated 11% positivity for toxigenic and 4% for non-toxigenic C. difficile. Among swabs, 32% of toxigenic C. difficile were resulted at 24 hours and 68% at 48 hours. Addition of 17% glycerol to BB-positive aliquots, for –80°C storage, supported 100% retrieval of C. difficile 7 months later. BB with confirmation provides a more sensitive method to detect patient colonization with toxigenic C. difficile and, by using VRE surveillance swabs, does not require additional patient samples. The simplified approach can be deployed across healthcare settings to support C. difficile -prevention programs. Importance: C. difficile infections are the most prevalent HAIs, causing substantive mortality, morbidity, and economic burden. Among HAIs, C. difficile remains the one pathogen lacking scalable surveillance strategies for clinical microbiology labs. We present an optimized strategy to enable C . difficile surveillance testing across broad clinical settings to enable prevention programs for this pathogen.